Listed

CNS Pharmaceuticals, Inc.

CNSPNasdaqCIK 1729427HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$2.7m, Q2 FY2026
Net income−$2.6m, Q2 FY2026
CNS Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$k3,411Research and development, Q3 FY2023, three months to 2023-09-30$3.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure4,272Research and development, Q4 FY2023, three months to 2023-12-31$4.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001683168-25-002139. Derived: 12-month figure less the 9-month figure.Report this figure2,430Research and development, Q1 FY2024, three months to 2024-03-31$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure1,117Research and development, Q2 FY2024, three months to 2024-06-30$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure4,245Research and development, Q3 FY2024, three months to 2024-09-30$4.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure1,498Research and development, Q4 FY2024, three months to 2024-12-31$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure3,243Research and development, Q1 FY2025, three months to 2025-03-31$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure1,167Research and development, Q2 FY2025, three months to 2025-06-30$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure2,197Research and development, Q3 FY2025, three months to 2025-09-30$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure3,165Research and development, Q4 FY2025, three months to 2025-12-31$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure3,544Research and development, Q1 FY2026, three months to 2026-03-31$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure1,201Research and development, Q2 FY2026, three months to 2026-06-30$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Operating income$k(4,534)Operating income, Q3 FY2023, three months to 2023-09-30−$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure(5,379)Operating income, Q4 FY2023, three months to 2023-12-31−$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001683168-25-002139. Derived: 12-month figure less the 9-month figure.Report this figure(3,545)Operating income, Q1 FY2024, three months to 2024-03-31−$3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure(2,528)Operating income, Q2 FY2024, three months to 2024-06-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure(5,629)Operating income, Q3 FY2024, three months to 2024-09-30−$5.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure(3,200)Operating income, Q4 FY2024, three months to 2024-12-31−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure(4,338)Operating income, Q1 FY2025, three months to 2025-03-31−$4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure(2,409)Operating income, Q2 FY2025, three months to 2025-06-30−$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure(3,253)Operating income, Q3 FY2025, three months to 2025-09-30−$3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure(5,986)Operating income, Q4 FY2025, three months to 2025-12-31−$6.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure(4,975)Operating income, Q1 FY2026, three months to 2026-03-31−$5.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure(2,700)Operating income, Q2 FY2026, three months to 2026-06-30−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Interest expense$k1.8Interest expense, Q3 FY2023, three months to 2023-09-30$1.8k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-14, accession 0001683168-23-008144.Report this figure2.9Interest expense, Q4 FY2023, three months to 2023-12-31$2.9k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-04-01, accession 0001683168-24-002032. Derived: 12-month figure less the 9-month figure.Report this figure6.6Interest expense, Q1 FY2024, three months to 2024-03-31$6.6k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-15, accession 0001683168-24-003531.Report this figure4.5Interest expense, Q2 FY2024, three months to 2024-06-30$4.5k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure2.3Interest expense, Q3 FY2024, three months to 2024-09-30$2.3k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure2.8Interest expense, Q4 FY2024, three months to 2024-12-31$2.8k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure6.2Interest expense, Q1 FY2025, three months to 2025-03-31$6.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure4.0Interest expense, Q2 FY2025, three months to 2025-06-30$4.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure2.1Interest expense, Q3 FY2025, three months to 2025-09-30$2.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure2.7Interest expense, Q4 FY2025, three months to 2025-12-31$2.7k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure6.1Interest expense, Q1 FY2026, three months to 2026-03-31$6.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure4.0Interest expense, Q2 FY2026, three months to 2026-06-30$4.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Net income$k(4,523)Net income, Q3 FY2023, three months to 2023-09-30−$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure(5,375)Net income, Q4 FY2023, three months to 2023-12-31−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001683168-25-002139. Derived: 12-month figure less the 9-month figure.Report this figure(3,545)Net income, Q1 FY2024, three months to 2024-03-31−$3.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure(2,531)Net income, Q2 FY2024, three months to 2024-06-30−$2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure(5,606)Net income, Q3 FY2024, three months to 2024-09-30−$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure(3,176)Net income, Q4 FY2024, three months to 2024-12-31−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure(4,301)Net income, Q1 FY2025, three months to 2025-03-31−$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure(2,375)Net income, Q2 FY2025, three months to 2025-06-30−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure(3,218)Net income, Q3 FY2025, three months to 2025-09-30−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure(5,956)Net income, Q4 FY2025, three months to 2025-12-31−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure(4,937)Net income, Q1 FY2026, three months to 2026-03-31−$4.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure(2,588)Net income, Q2 FY2026, three months to 2026-06-30−$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Diluted EPS$ per share(54.14)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$54.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figurenot reported(1020.48)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1020.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure(4049.20)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$4049.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure(153.20)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$153.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figurenot reported(18.93)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$18.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure(6.42)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$6.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure(5.76)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$5.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figurenot reported(7.30)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$7.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure(0.38)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Basic EPS$ per share(54.14)Basic EPS, Q3 FY2023, three months to 2023-09-30−$54.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figurenot reported(1020.48)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1020.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure(4049.20)Basic EPS, Q2 FY2024, three months to 2024-06-30−$4049.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure(153.20)Basic EPS, Q3 FY2024, three months to 2024-09-30−$153.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figurenot reported(18.93)Basic EPS, Q1 FY2025, three months to 2025-03-31−$18.93 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure(6.42)Basic EPS, Q2 FY2025, three months to 2025-06-30−$6.42 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure(5.76)Basic EPS, Q3 FY2025, three months to 2025-09-30−$5.76 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figurenot reported(7.30)Basic EPS, Q1 FY2026, three months to 2026-03-31−$7.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure(0.38)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure

Balance sheet

Cash and equivalents$20.0m, Q2 FY2026
Shareholders' equity$18.2m, Q2 FY2026
CNS Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m0.9Cash and equivalents, Q3 FY2023, at 2023-09-30$909.5k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0001683168-23-008144.Report this figure0.5Cash and equivalents, FY2023, at 2023-12-31$548.7k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001683168-25-002139.Report this figure0.8Cash and equivalents, Q1 FY2024, at 2024-03-31$815.2k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-15, accession 0001683168-24-003531.Report this figure1.5Cash and equivalents, Q2 FY2024, at 2024-06-30$1.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0001683168-24-005711.Report this figure7.0Cash and equivalents, Q3 FY2024, at 2024-09-30$7.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure6.5Cash and equivalents, FY2024, at 2024-12-31$6.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-31, accession 0001683168-26-002550.Report this figure13.0Cash and equivalents, Q1 FY2025, at 2025-03-31$13.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure12.1Cash and equivalents, Q2 FY2025, at 2025-06-30$12.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure9.9Cash and equivalents, Q3 FY2025, at 2025-09-30$9.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure7.2Cash and equivalents, FY2025, at 2025-12-31$7.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure3.0Cash and equivalents, Q1 FY2026, at 2026-03-31$3.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure20.0Cash and equivalents, Q2 FY2026, at 2026-06-30$20.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Current assets$m2.1Current assets, Q3 FY2023, at 2023-09-30$2.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001683168-23-008144.Report this figure1.6Current assets, FY2023, at 2023-12-31$1.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001683168-25-002139.Report this figure1.6Current assets, Q1 FY2024, at 2024-03-31$1.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0001683168-24-003531.Report this figure2.1Current assets, Q2 FY2024, at 2024-06-30$2.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001683168-24-005711.Report this figure7.4Current assets, Q3 FY2024, at 2024-09-30$7.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure8.7Current assets, FY2024, at 2024-12-31$8.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-31, accession 0001683168-26-002550.Report this figure13.7Current assets, Q1 FY2025, at 2025-03-31$13.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure14.1Current assets, Q2 FY2025, at 2025-06-30$14.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure11.4Current assets, Q3 FY2025, at 2025-09-30$11.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure8.1Current assets, FY2025, at 2025-12-31$8.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure4.1Current assets, Q1 FY2026, at 2026-03-31$4.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure21.9Current assets, Q2 FY2026, at 2026-06-30$21.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Total assets$m2.3Total assets, Q3 FY2023, at 2023-09-30$2.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001683168-23-008144.Report this figure1.7Total assets, FY2023, at 2023-12-31$1.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001683168-25-002139.Report this figure1.7Total assets, Q1 FY2024, at 2024-03-31$1.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0001683168-24-003531.Report this figure2.5Total assets, Q2 FY2024, at 2024-06-30$2.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001683168-24-005711.Report this figure7.4Total assets, Q3 FY2024, at 2024-09-30$7.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure8.7Total assets, FY2024, at 2024-12-31$8.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-31, accession 0001683168-26-002550.Report this figure13.7Total assets, Q1 FY2025, at 2025-03-31$13.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure14.5Total assets, Q2 FY2025, at 2025-06-30$14.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure11.9Total assets, Q3 FY2025, at 2025-09-30$11.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure8.6Total assets, FY2025, at 2025-12-31$8.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure4.7Total assets, Q1 FY2026, at 2026-03-31$4.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure21.9Total assets, Q2 FY2026, at 2026-06-30$21.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Current liabilities$m4.1Current liabilities, Q3 FY2023, at 2023-09-30$4.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001683168-23-008144.Report this figure6.1Current liabilities, FY2023, at 2023-12-31$6.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001683168-25-002139.Report this figure6.1Current liabilities, Q1 FY2024, at 2024-03-31$6.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0001683168-24-003531.Report this figure6.8Current liabilities, Q2 FY2024, at 2024-06-30$6.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001683168-24-005711.Report this figure4.1Current liabilities, Q3 FY2024, at 2024-09-30$4.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure2.5Current liabilities, FY2024, at 2024-12-31$2.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-31, accession 0001683168-26-002550.Report this figure2.8Current liabilities, Q1 FY2025, at 2025-03-31$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure1.4Current liabilities, Q2 FY2025, at 2025-06-30$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure2.0Current liabilities, Q3 FY2025, at 2025-09-30$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure4.1Current liabilities, FY2025, at 2025-12-31$4.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure4.6Current liabilities, Q1 FY2026, at 2026-03-31$4.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure3.7Current liabilities, Q2 FY2026, at 2026-06-30$3.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Total liabilities$m4.1Total liabilities, Q3 FY2023, at 2023-09-30$4.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001683168-23-008144.Report this figure6.1Total liabilities, FY2023, at 2023-12-31$6.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001683168-25-002139.Report this figure6.1Total liabilities, Q1 FY2024, at 2024-03-31$6.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0001683168-24-003531.Report this figure6.8Total liabilities, Q2 FY2024, at 2024-06-30$6.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001683168-24-005711.Report this figure4.1Total liabilities, Q3 FY2024, at 2024-09-30$4.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure2.5Total liabilities, FY2024, at 2024-12-31$2.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-31, accession 0001683168-26-002550.Report this figure2.8Total liabilities, Q1 FY2025, at 2025-03-31$2.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure1.4Total liabilities, Q2 FY2025, at 2025-06-30$1.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure2.0Total liabilities, Q3 FY2025, at 2025-09-30$2.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure4.1Total liabilities, FY2025, at 2025-12-31$4.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure4.6Total liabilities, Q1 FY2026, at 2026-03-31$4.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure3.7Total liabilities, Q2 FY2026, at 2026-06-30$3.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(1.7)Shareholders' equity, Q3 FY2023, at 2023-09-30−$1.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure(4.4)Shareholders' equity, FY2023, at 2023-12-31−$4.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-31, accession 0001683168-26-002550.Report this figure(4.4)Shareholders' equity, Q1 FY2024, at 2024-03-31−$4.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure(4.3)Shareholders' equity, Q2 FY2024, at 2024-06-30−$4.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure3.4Shareholders' equity, Q3 FY2024, at 2024-09-30$3.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure6.2Shareholders' equity, FY2024, at 2024-12-31$6.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure11.0Shareholders' equity, Q1 FY2025, at 2025-03-31$11.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure13.1Shareholders' equity, Q2 FY2025, at 2025-06-30$13.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure9.9Shareholders' equity, Q3 FY2025, at 2025-09-30$9.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure4.5Shareholders' equity, FY2025, at 2025-12-31$4.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure0.1Shareholders' equity, Q1 FY2026, at 2026-03-31$71.0k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure18.2Shareholders' equity, Q2 FY2026, at 2026-06-30$18.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure

Cash flow

Operating cash flow−$3.5m, Q2 FY2026
Capital expenditure$3.8k, Q2 FY2026
CNS Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(3,376)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001683168-24-008125. Derived: 9-month figure less the 6-month figure.Report this figure(2,536)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001683168-25-002139. Derived: 12-month figure less the 9-month figure.Report this figure(3,192)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure(1,650)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001683168-25-006162. Derived: 6-month figure less the 3-month figure.Report this figure(6,800)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$6.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001683168-25-008466. Derived: 9-month figure less the 6-month figure.Report this figure(5,471)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure(3,242)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure(5,344)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001683168-26-006224. Derived: 6-month figure less the 3-month figure.Report this figure(2,173)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001683168-25-008466. Derived: 9-month figure less the 6-month figure.Report this figure(3,052)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure(4,649)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure(3,539)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001683168-26-006224. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k1.7Capital expenditure, Q3 FY2023, three months to 2023-09-30$1.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-14, accession 0001683168-24-008125. Derived: 9-month figure less the 6-month figure.Report this figure2.2Capital expenditure, Q4 FY2023, three months to 2023-12-31$2.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001683168-25-002139. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reported4.2Capital expenditure, Q4 FY2024, three months to 2024-12-31$4.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-31, accession 0001683168-26-002550. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001683168-26-006224. Derived: 6-month figure less the 3-month figure.Report this figurenot reportednot reported6.2Capital expenditure, Q1 FY2026, three months to 2026-03-31$6.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure3.8Capital expenditure, Q2 FY2026, three months to 2026-06-30$3.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001683168-26-006224. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)6.84m, Q2 FY2026
CNS Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)k shares1,334Diluted shares (weighted), Q3 FY2022, three months to 2022-09-301,334,417 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001683168-23-008144.Report this figure1,906Diluted shares (weighted), Q1 FY2023, three months to 2023-03-311,906,494 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-15, accession 0001683168-24-003531.Report this figure77.5Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3077,547 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001683168-24-005711.Report this figure83.5Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3083,542 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001683168-24-008125.Report this figure3.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-313,474 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001683168-25-003733.Report this figure0.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30625 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001683168-25-006162.Report this figure36.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3036,593 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure227Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31227,220 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure370Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30370,127 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure559Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30558,868 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001683168-25-008466.Report this figure676Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31676,172 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001683168-26-003847.Report this figure6,838Diluted shares (weighted), Q2 FY2026, three months to 2026-06-306,838,205 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure

Shares outstanding: 1.46mShares outstanding, period not labelled, at 2026-08-111,461,449 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-12, accession 0001683168-26-006224.Report this figure at Aug 11, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.